ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$135.21|
|52 Week High||US$138.15|
|52 Week Low||US$101.81|
|1 Month Change||3.32%|
|3 Month Change||24.32%|
|1 Year Change||20.06%|
|3 Year Change||52.87%|
|5 Year Change||120.28%|
|Change since IPO||286.31%|
Recent News & Updates
AbbVie Will Keep Going Higher
AbbVie continues to be under-appreciated and undervalued. The company's revenue, EPS, and dividend arc all consistent growers. Shares appear capable of appreciating 20-30% this year.
AbbVie: Doing The RIG(HT) Thing
Aside of performance and volatility, proper diversification and proper allocation/s are crucial. Don't bet too much on anything, no matter how "sexy" it may look. RIG's largest position has a 5.2% allocation and it's up 16.5% over the past six weeks (since inception date). At the same time, RIG's best/worst position is up/down 26.8%/18.3%. Luckily, allocation to the best is 6.5x bigger than allocation to the worst.
|ABBV||US Biotechs||US Market|
Return vs Industry: ABBV exceeded the US Biotechs industry which returned -18.4% over the past year.
Return vs Market: ABBV exceeded the US Market which returned 10.2% over the past year.
|ABBV Average Weekly Movement||2.6%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ABBV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.
AbbVie Fundamentals Summary
|ABBV fundamental statistics|
Is ABBV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABBV income statement (TTM)|
|Cost of Revenue||US$16.44b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 02, 2022
|Earnings per share (EPS)||4.22|
|Net Profit Margin||13.53%|
How did ABBV perform over the long term?See historical performance and comparison
4.2%Current Dividend Yield
Is AbbVie undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABBV ($135.21) is trading below our estimate of fair value ($308.63)
Significantly Below Fair Value: ABBV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ABBV is poor value based on its PE Ratio (32x) compared to the US Biotechs industry average (23.5x).
PE vs Market: ABBV is poor value based on its PE Ratio (32x) compared to the US market (17x).
Price to Earnings Growth Ratio
PEG Ratio: ABBV is poor value based on its PEG Ratio (7.4x)
Price to Book Ratio
PB vs Industry: ABBV is overvalued based on its PB Ratio (17.6x) compared to the US Biotechs industry average (2.1x).
How is AbbVie forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABBV's forecast earnings growth (4.3% per year) is above the savings rate (2%).
Earnings vs Market: ABBV's earnings (4.3% per year) are forecast to grow slower than the US market (13% per year).
High Growth Earnings: ABBV's earnings are forecast to grow, but not significantly.
Revenue vs Market: ABBV's revenue (0.5% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: ABBV's revenue (0.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABBV's Return on Equity is forecast to be very high in 3 years time (95.7%).
How has AbbVie performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABBV has a large one-off loss of $10.7B impacting its September 30 2021 financial results.
Growing Profit Margin: ABBV's current net profit margins (13.5%) are lower than last year (18%).
Past Earnings Growth Analysis
Earnings Trend: ABBV's earnings have grown by 0.9% per year over the past 5 years.
Accelerating Growth: ABBV's earnings growth over the past year (1.9%) exceeds its 5-year average (0.9% per year).
Earnings vs Industry: ABBV earnings growth over the past year (1.9%) underperformed the Biotechs industry 11%.
Return on Equity
High ROE: Whilst ABBV's Return on Equity (55.55%) is outstanding, this metric is skewed due to their high level of debt.
How is AbbVie's financial position?
Financial Position Analysis
Short Term Liabilities: ABBV's short term assets ($29.0B) exceed its short term liabilities ($28.5B).
Long Term Liabilities: ABBV's short term assets ($29.0B) do not cover its long term liabilities ($106.7B).
Debt to Equity History and Analysis
Debt Level: ABBV's net debt to equity ratio (504.4%) is considered high.
Reducing Debt: ABBV's debt to equity ratio has increased from 578.5% to 594.7% over the past 5 years.
Debt Coverage: ABBV's debt is well covered by operating cash flow (27.9%).
Interest Coverage: ABBV's interest payments on its debt are well covered by EBIT (8.3x coverage).
What is AbbVie current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ABBV's dividend (4.17%) is higher than the bottom 25% of dividend payers in the US market (1.35%).
High Dividend: ABBV's dividend (4.17%) is in the top 25% of dividend payers in the US market (3.48%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, ABBV has been paying a dividend for less than 10 years.
Growing Dividend: ABBV's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (123.2%), ABBV's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ABBV's dividends in 3 years are forecast to be covered by earnings (50.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Gonzalez (67 yo)
Mr. Richard A. Gonzalez, also known as Rick, serves as the Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD24.01M) is above average for companies of similar size in the US market ($USD11.29M).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
Experienced Management: ABBV's management team is considered experienced (3.2 years average tenure).
Experienced Board: ABBV's board of directors are considered experienced (9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ABBV insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AbbVie Inc.'s employee growth, exchange listings and data sources
- Name: AbbVie Inc.
- Ticker: ABBV
- Exchange: NYSE
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$239.035b
- Shares outstanding: 1.77b
- Website: https://www.abbvie.com
Number of Employees
- AbbVie Inc.
- 1 North Waukegan Road
- North Chicago
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 23:47|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.